Atlas Trials

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Clinical trial NCT02921022 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02921022
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Pancreatic CancerAdvanced Pancreatic Ductal Adenocarcinoma
Start date
2016-10-01
Primary completion
2026-10-01
Enrollment
110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.